NEOPLASMS BY SITE

This study tests a new oral drug called pocenbrodib, alone or with another drug (darolutamide), in 120 men with metastatic castration-resistant prostate cancer (mCRPC). The goal is to find safe doses and see if the combination can slow cancer growth. It is an early-stage trial, s…

This Phase 3 study tests a new medicine called PF-08634404 combined with chemotherapy for people whose colorectal cancer has spread. About 800 participants will be randomly assigned to receive either the new drug or the approved drug Avastin, both with chemo. The goal is to see i…

This early-stage trial tests whether a specially engineered herpes virus (G207) is safe to inject directly into the brain tumors of children whose cancer has returned. Up to 24 children aged 3 to 21 will receive the virus, and some will also get a low dose of radiation to help th…

This trial tests atezolizumab, a drug already approved for several cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). The goal is to see if the drug can shrink tumors or stop them from growing for at least 24 wee…

This trial tests capmatinib, a drug already approved for certain lung cancers, in adults with rare cancers that have specific MET gene changes. About 30 participants will receive the drug to see if it can shrink tumors or stop them from growing for at least 24 weeks. The goal is …

This trial tests whether giving two immunotherapy drugs (nivolumab with or without relatlimab) before surgery can help people with stage II-IIIa bladder cancer avoid bladder removal. About 90 adults will be randomly assigned to one of the two drug combinations. The main goal is t…

This trial is testing a drug called entrectinib (Rozlytrek) in people with rare cancers that have a specific genetic change called a ROS1 gene fusion. The drug is already approved for some lung cancers, and researchers want to see if it can help shrink or control other tumor type…

This study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. The trial involves about …

This study tests a drug called alectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change called ALK. About 30 adults, teens, and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops…